Registered title, quoted from ClinicalTrials.gov
A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07511114, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
1. Have previously received systemic or local treatments, including chemotherapy;
Exclusion criterion 1
2. Have previously undergone autologous stem cell transplantation;
Exclusion criterion 2
12. Patients with positive HBsAg test results must undergo HBV DNA testing and can only be enrolled after becoming negative. Additionally, if the HBsAg test result is negative but the HBcAb test result is positive (regardless of the HBsAb status), HBV DNA testing is also required. If the result is positive, treatment must be administered until becoming negative before enrollment;
Exclusion criterion 12
4. ECOG performance status score of 0, 1, or 2;
Inclusion criterion 4
7. Laboratory test values during screening: (unless caused by lymphoma); A. Neutrophil count <1.5*10\^9/L; B. Platelet count < 75 x 10\^9/L; C. ALT or AST is 2 times higher than the upper limit of normal, and AKP and bilirubin are 1.5 times higher than the upper limit of normal; D. Creatinine level is higher than 1.5 times the upper limit of normal;
Exclusion criterion 7
3. Previously had a history of other malignant tumors, excluding basal cell carcinoma and cervical carcinoma in situ;
Exclusion criterion 3
11. Individuals infected with HIV.
Exclusion criterion 11
10. Pregnant or lactating women;
Exclusion criterion 10
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07511114, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- 1. Histopathological diagnosis confirmed as diffuse large B-cell lymphoma, with CD20 positivity;
- 2. Simultaneous expression of MYC and BCL2, according to the WHO standard for immunohistochemistry: MYC ≥ 40%, BCL2 ≥ 50%
- 3. Age ≥ 18 years old and ≤ 75 years old;
- 4. ECOG performance status score of 0, 1, or 2;
- 5. International Prognostic Index (IPI) > 1
- 6. No history of malignant tumor; no concurrent occurrence of other tumors;
- 7. Patients with an expected lifespan of at least 6 months, as determined by the researcher;
- 8. The patient or their legal representative must provide written informed consent before undergoing any special examinations or procedures in the study.
Exclusion Criteria:
- 1. Have previously received systemic or local treatments, including chemotherapy;
- 2. Have previously undergone autologous stem cell transplantation;
- 3. Previously had a history of other malignant tumors, excluding basal cell carcinoma and cervical carcinoma in situ;
- 4. Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, etc;
- 5. Primary central nervous system lymphoma;
- 6. Left ventricular ejection fraction (LVEF) is less than or equal to 50%;
- 7. Laboratory test values during screening: (unless caused by lymphoma); A. Neutrophil count <1.5*10\^9/L; B. Platelet count < 75 x 10\^9/L; C. ALT or AST is 2 times higher than the upper limit of normal, and AKP and bilirubin are 1.5 times higher than the upper limit of normal; D. Creatinine level is higher than 1.5 times the upper limit of normal;
- 8. Other concurrent and uncontrolled medical conditions that the researcher believes will affect the patient's participation in the study.
- 9. Patients with mental illness or other patients known or suspected to be unable to fully comply with the study protocol;
- 10. Pregnant or lactating women;
- 11. Individuals infected with HIV.
- 12. Patients with positive HBsAg test results must undergo HBV DNA testing and can only be enrolled after becoming negative. Additionally, if the HBsAg test result is negative but the HBcAb test result is positive (regardless of the HBsAb status), HBV DNA testing is also required. If the result is positive, treatment must be administered until becoming negative before enrollment;
Quoted from ClinicalTrials.gov, NCT07511114, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07511114, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.